BCR-ABL Kinase Domain Mutations near me in Bangalore

Chronic Myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome, the product of the t(9;22)(q34;q11) translocation. This translocation results in the BCR/ABL fusion protein with constitutive ABL tyrosine kinase activity. The kinase inhibitor imatinib inhibits ABL kinase activity and is now the standard of care for early-phase CML.

Prolonged treatment with Imatinib can lead to drug resistance, especially in patients with advanced disease. This test detects greater than 90 percent of ABL mutations that may lead to Imatinib resistance, including the important T315I and P-loop mutations.